Pluristem (PSTI) Resumes, Drops 15%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Jefferies Lower Target on Pluristem Therapeutics (PSTI) on FDA Setback
June 5, 2013 7:56 AM EDTJefferies cut its price target on Hold-rated Pluristem Therapeutics (NASDAQ: PSTI) from $3.50 to $3 after the FDA has placed its Phase 2 for lead stem-cell product candidate PLX-PAD on clinical hold in light of a single episode of serious allergic reaction. The firm said this creates... More
Pluristem Therapeutics (PSTI) to resume trading at 9:50am ET
June 4, 2013 9:17 AM EDTPluristem Therapeutics, Inc. (NASDAQ: PSTI) to resume trading at 9:50am EDT.... More
Pluristem Therapeutics (PSTI) trading halted, news pending.
June 4, 2013 8:58 AM EDTPluristem Therapeutics, Inc. (NASDAQ: PSTI) trading halted for news.... More
